TEVA News and Press, Teva Pharmaceutical Industries Limited American Depositary Shares From 05/02/24

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the 2024 Bank of America Healthcare Conference on Tuesday, May 14, 2024. The presentation will begin at 8:40 A.M. Pacific Time (11:40 A.M. Eastern Time). T...

2024-05-02 12:28:33 ET Summary EXEL continues to successfully implement Farallon's restructuring suggestions. A pivotal decision on cabo's current patent litigation is due by end of 1H'24. Multiple billions of potential revenue are at stake. I'm not holding shares through the ...

Teva’s 2023 Healthy Future Report highlights the Company’s renewed sustainability strategy, which guides Teva in addressing global challenges while also supporting its business, allowing for the continued supply of medicines for patients New ambitious targets are centered on net...

2024-04-30 12:18:17 ET More on AstraZeneca, GSK, etc. AstraZeneca: A Triple Shot Of Income, Growth, And Value Novo Nordisk: Medicare Coverage To Unlock Another Big Market For Wegovy AstraZeneca: Strong In A Weak Market GSK Q1 2024 Earnings Preview Ast...

2024-04-30 11:56:42 ET More on Alvotech Alvotech: Consider Buying As Positive Q1 Earnings Release Likely Alvotech (ALVO) Q4 2023 Earnings Call Transcript Alvotech/Teva bring new partner to expand access for Humira biosimilar in U.S. FDA approves Alvotech bios...

Alvotech will manufacture its high-concentration interchangeable biosimilar to Humira® (adalimumab) for Quallent Pharmaceuticals The strategic agreement is in alignment with Alvotech’s U.S. commercialization agreement with Teva Pharmaceuticals The high-concentration in...

2024-04-26 14:09:10 ET More on AbbVie AbbVie Inc. (ABBV) Q1 2024 Earnings Call Transcript AbbVie's Q1: Positive Surprise AbbVie Q1 Earnings Preview: No Repeat Of Last Year's Q1 Disappointment AbbVie Q1 report beats Street despite plunging Humira sales ...

2024-04-24 07:15:00 ET Summary Sound Shore Fund, Inc. is registered as a diversified, open-end management investment company. The investment objective of the Fund is growth of capital. The Sound Shore Fund Investor Class and Institutional Class advanced 17.05% and 17.10%, respecti...

2024-04-22 10:55:53 ET More on Vanda Pharmaceuticals Vanda Pharmaceuticals: Fanapt Bipolar Win Doesn't Change Much Vanda Pharmaceuticals' Portfolio Likely Has Upside From 2024 Approvals, Underpinned By Cash Vanda Pharmaceuticals Inc. (VNDA) Q4 2023 Earnings Call Tran...

2024-04-19 07:03:48 ET Summary Since my last article, the company's share price has fallen about 10% despite its quarterly revenue growth and achieving significant success in developing experimental drugs. In addition to growing sales of next-generation drugs such as Ngenla, Bosul...